N
Nathan Segall
Researcher at Fred Hutchinson Cancer Research Center
Publications - 6
Citations - 2847
Nathan Segall is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Randomized controlled trial & Placebo. The author has an hindex of 4, co-authored 5 publications receiving 2748 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
TL;DR: The mRNA-1273 vaccine as discussed by the authors is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.
Journal ArticleDOI
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial.
Judith Absalon,Nathan Segall,Stan L. Block,Ingrid L. Scully,Peter C. Giardina,James Peterson,Wendy Watson,William C. Gruber,Kathrin U. Jansen,Yahong Peng,Samantha Munson,Danka Pavliakova,Daniel A. Scott,Annaliesa S. Anderson +13 more
TL;DR: GBS serotype-specific IgG geometric mean concentrations increased by 1 week after vaccination for all GBS6 groups, peaked at 2 weeks, stabilised by 1 month, and declined gradually but remained higher than placebo at 6 months.
Journal ArticleDOI
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.
Timo Vesikari,Joanne M. Langley,Nathan Segall,Brian J. Ward,Curtis Cooper,Guillaume Poliquin,Bruce Smith,Soren Gantt,Janet E McElhaney,Marc Dionne,Pierre Van Damme,Isabel Leroux-Roels,Geert Leroux-Roels,Nathalie Machluf,Johanna Spaans,Bebi Yassin-Rajkumar,David E. Anderson,Vlad Popovic,Francisco Diaz-Mitoma,Janet E. McElhaney,Bruce Rankin,Carl Griffin,Mark A. Turner,Judith Kirstein,Barbara E. Rizzardi,Hayes Williams,Anitta Ahonen,Olli Henriksson,Benita Ukkonen,Marita Paassilta +29 more
TL;DR: In this article, the authors compared the seroprotation rate (SPR) of hepatitis B vaccination in adults with a tri-antigenic hepatitis B vaccine (TAV) and a mono-antigamic vaccine (MAV) in 28 community and hospital sites in the USA, Finland, Canada, and Belgium.
Journal ArticleDOI
Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial.
Timo Vesikari,Adam Finn,Pierre Van Damme,Isabel Leroux-Roels,Geert Leroux-Roels,Nathan Segall,Azhar Toma,Gerald Vallieres,Ronnie Aronson,Dennis Reich,Samir Arora,Peter Ruane,Clancy L. Cone,Michael Manns,Catherine Cosgrove,Saul N. Faust,Saul N. Faust,M N Ramasamy,Nathalie Machluf,Johanna Spaans,Bebi Yassin-Rajkumar,David E. Anderson,Vlad Popovic,Francisco Diaz-Mitoma,Bruce Rankin,Mary B Manning,Carl Griffin,Amina Z Haggag,Mark E Kutner,Mark A. Turner,Barbara E. Rizzardi,Williams Hayes,Michael Levin,Hamilton Sah,Naveen Garg,Aino Forsten,Ilkka Seppä,Maija Rössi,Anitta Ahonen,Olli Henriksson,Benita Ukkonen,Satu Kokko,Outi Laajalahti,Pauliina Paavola +43 more
TL;DR: In this article, the authors evaluated the safety and reactogenicity of 3A-HBV vs single-antigen (1A) vaccines after 2 and 3 vaccine doses.
Journal ArticleDOI
Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
Mark Turner,Athanasia Papadimitriou,Peter Winkle,Nathan Segall,Michael Levin,Matthew Doust,Casey Johnson,Gregg Lucksinger,Carlos Fierro,Paul Pickrell,Marsha Raanan,Vianney Tricou,Astrid Borkowski,Derek Wallace +13 more
TL;DR: The primary objective was to show immunologic equivalence in terms of geometric mean titers of neutralizing antibodies to the four dengue serotypes one month after one dose of the lyophilized and liquid TAK-003 formulation.